ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC

oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]

AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.